Spotlight on allogeneic CAR-T
CAR-T therapy involves utilizing a patient’s own T-cells to treat cancer and, as a technique, has rapidly expanded over the past year. However, obtaining patient samples can be problematic, time-consuming and costly. To make the use of the economy-of-scale, there has been a move away from autologous therapies to allogeneic therapies. Allogeneic CAR-T therapies could be used ‘off-the-shelf’, although that transition is still in its early days.
This Spotlight will aim to review the advances in allogeneic CAR-T therapy, the challenges the treatment has faced and the future as we advance allogeneic alternatives. In association with CellGenix GmbH and Lonza Pharma & Biotech, we will investigate the current state-of-the-art in allogeneic CAR-T manufacturing. Learn more about the obstacles scientists, developers and manufacturers around the world are facing. Discover top tips and insight into improving your protocols and processes, plus find out where the field may evolve in the future.